Success Metrics

Clinical Success Rate
100.0%

Based on 10 completed trials

Completion Rate
100%(10/10)
Active Trials
1(8%)
Results Posted
50%(5 trials)

Phase Distribution

Ph phase_1
2
17%
Ph phase_2
2
17%
Ph phase_3
4
33%
Ph phase_4
1
8%

Phase Distribution

2

Early Stage

2

Mid Stage

5

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
2(22.2%)
Phase 2Efficacy & side effects
2(22.2%)
Phase 3Large-scale testing
4(44.4%)
Phase 4Post-market surveillance
1(11.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

10 of 10 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

12

all time

Status Distribution
Active(1)
Completed(10)
Other(1)

Detailed Status

Completed10
Recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (22.2%)
Phase 22 (22.2%)
Phase 34 (44.4%)
Phase 41 (11.1%)

Trials by Status

recruiting18%
completed1083%
unknown18%

Recent Activity

1 active trials
Showing 5 of 12
completedphase_2

A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases

NCT05755035
recruitingphase_3

A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

NCT06747351
completedphase_1

A Study of TAK-881 and HyQvia in Healthy Adults

NCT06895967
completedphase_3

Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP

NCT02955355
completedphase_1

A Study to Assess the Tolerability, Safety, and Pharmacokinetics of Subcutaneous Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) With Ramp-up and No Ramp-up Dosing in Healthy Adult Participants

NCT04578535
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT05755035Phase 2

A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases

Completed
NCT06747351Phase 3

A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Recruiting
NCT06895967Phase 1

A Study of TAK-881 and HyQvia in Healthy Adults

Completed
NCT02955355Phase 3

Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP

Completed
NCT04578535Phase 1

A Study to Assess the Tolerability, Safety, and Pharmacokinetics of Subcutaneous Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) With Ramp-up and No Ramp-up Dosing in Healthy Adult Participants

Completed
NCT03277313Phase 3

Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects

Completed
NCT03054181

Facilitated Immunoglobulin Administration Registry and Outcomes Study (FIGARO)

Completed
NCT02549170Phase 3

A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Completed
NCT03116347Phase 4

Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric PIDD Subjects

Completed
NCT02593188

Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global)

Completed
NCT03829826

Efficacy and Mechanism of Action of SCIg in Patients With Stiff Person Syndrome (SPS)

Unknown
NCT02556437Phase 2

Efficacy and Safety of HyQvia (Immunoglobulin 10% With Recombinant Hyaluronidase) in Multifocal Motor Neuropathy (MMN)

Completed

All 12 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
12